The endocannabinoid system as pharmacological target derived from its CNS role in energy homeostasis and reward. Applications in eating disorders and addiction

Pharmaceuticals

Volumn 4, Issue 8, 2011, Pages 1101-1136

  Viveros, Maria Paz ^a   Bermúdez Silva, Francisco Javier ^b,c   Lopez Rodriguez, Ana Belén ^a   Wagner, Edward J ^d  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c INSTITUT FRANÇOIS MAGENDIE   (France)

^d WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Addiction; Anorexia nervosa; Bulimia nervosa; Cannabinoid based therapy; CB1; CB2; Drug abuse; Eating disorders; Energy balance; FAAH

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABIS; DIAZEPAM; DOPAMINE; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; NABILONE; RIMONABANT; TETRAHYDROCANNABINOL;

ANOREXIA NERVOSA; BULIMIA; CACHEXIA; CANCER PAIN; CENTRAL NERVOUS SYSTEM FUNCTION; CHEMOTHERAPY INDUCED EMESIS; DEPRESSION; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG DEPENDENCE; DRUG RESPONSE; EATING DISORDER; ENERGY BALANCE; ENZYME ACTIVITY; ENZYME INACTIVATION; FATTY ACID AMIDE HYDROLASE 1 GENE; GENE; GENE ACTIVATION; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; HYPERSENSITIVITY REACTION; LIGAND BINDING; MULTIPLE SCLEROSIS; NEUROMODULATION; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; REWARD; SIGNAL TRANSDUCTION; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT;

EID: 80052207916     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph4081101     Document Type: Review

References (247)

1. Matias, I.; di Marzo, V. Endocannabinoids and the control of energy balance. Trends Endocrinol. Metab. 2007, 18, 27-37.
2. Katona, I.; Freund, T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 2008, 14, 923-930.
3. Piomelli, D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003, 4, 873-884.
4. Valenti, M.; Cottone, E.; Martinez, R.; de Pedro, N.; Rubio, M.; Viveros, M.P.; Franzoni, M.F.; Delgado, M.J.; di Marzo, V. The endocannabinoid system in the brain of Carassius auratus and its possible role in the control of food intake. J. Neurochem. 2005, 95, 662-672.
5. Viveros, M.P.; Llorente, R.; Lopez-Gallardo, M.; Suarez, J.; Bermudez-Silva, F.; de la Fuente, M.; Rodriguez de Fonseca F.; Garcia-Segura, L.M. Sex-dependent alterations in response to maternal deprivation in rats. Psychoneuroendocrinology 2009, 34, S217-S226.
6. Wolf, S.A.; Bick-Sander, A.; Fabel, K.; Leal-Galicia, P.; Tauber, S.; Ramirez-Rodriguez, G.; Muller, A.; Melnik, A.; Waltinger, T.P.; Ullrich O.; et al. Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Commun. Signal. 2010, 8, 12.
7. Soltys, J.; Yushak, M.; Mao-Draayer, Y. Regulation of neural progenitor cell fate by anandamide. Biochem. Biophys. Res. Commun. 2010, 400, 21-26.
8. Galve-Roperh, I.; Palazuelos, J.; Aguado, T.; Guzman, M. The endocannabinoid system and the regulation of neural development: Potential implications in psychiatric disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259, 371-382.
9. Lutz, B. Endocannabinoid signals in the control of emotion. Curr. Opin. Pharmacol. 2009, 9, 46-52.
10. Viveros, M.P.; Marco, E.M.; File, S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 2005, 81, 331-342.
11. Viveros, M.P.; Marco, E.M.; Llorente, R.; Lopez-Gallardo, M. Endocannabinoid system and synaptic plasticity: Implications for emotional responses. Neural Plast. 2007, 2007, 52908.
12. Fowler, C.J.; Rojo, M.L.; Rodriguez-Gaztelumendi, A. Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity? Exp. Neurol. 2010, 224, 37-47.
13. Clapper, J.R.; Moreno-Sanz, G.; Russo, R.; Guijarro, A.; Vacondio, F.; Duranti, A.; Tontini, A.; Sanchini, S.; Sciolino, N.R.; Spradley J.M. et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 2010, 13, 1265-1270.
14. Solbrig, M.V.; Fan, Y.; Hermanowicz, N.; Morgese, M.G.; Giuffrida, A. A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats. Exp. Neurol. 2010, 226, 231-241.
15. Fernandez-Ruiz, J.; Hernandez, M.; Ramos, J.A. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS. Neurosci. Ther. 2010, 16, e72-e91.
16. Bermudez-Silva, F.J.; Viveros, M.P.; McPartland, J.M.; Rodriguez de Fonseca, F. The endocannabinoid system, eating behavior and energy homeostasis: The end or a new beginning? Pharmacol. Biochem. Behav. 2010, 95, 375-382.
17. Crespillo, A.; Suarez, J.; Bermudez-Silva, F.J.; Rivera, P.; Vida, M.; Alonso, M.; Palomino, A.; Lucena, M.A.; Serrano, A.; Perez-Martin M. et al. Expression of the cannabinoid system in muscle: Effects of a high-fat diet and CB1 receptor blockade. Biochem. J. 2010, 433, 175-185.
18. Fattore, L.; Melis, M.; Fadda, P.; Pistis, M.; Fratta, W. The endocannabinoid system and nondrug rewarding behaviours. Exp. Neurol. 2010, 224, 23-36.
19. Tam, J.; Liu, J.; Mukhopadhyay, B.; Cinar, R.; Godlewski, G.; Kunos, G. Endocannabinoids in liver disease. Hepatology 2011, 53, 346-355.
20. Zajicek, J.P.; Apostu, V.I. Role of cannabinoids in multiple sclerosis. CNS. Drugs. 2011, 25, 187-201.
21. Park, J.M.; Xian, X.S.; Choi, M.G.; Park, H.; Cho, Y.K.; Lee, I.S.; Kim, S.W.; Chung, I.S. Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells. J. Cell Biochem. 2011, 112, 1192-1205.
22. Palazuelos, J.; Aguado, T.; Pazos, M.R.; Julien, B.; Carrasco, C.; Resel, E.; Sagredo, O.; Benito, C.; Romero, J.; Azcoitia, I. et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009, 132, 3152-3164.
23. Amantea, D.; Spagnuolo, P.; Bari, M.; Fezza, F.; Mazzei, C.; Tassorelli, C.; Morrone, L.A.; Corasaniti, M.T.; Maccarrone, M.; Bagetta, G. Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol. FEBS J. 2007, 274, 4464-4775.
24. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
25. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N.E.; Schatz, A.R.; Gopher, A.; Almog, S.; Martin, B.R.; Compton, D.R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50, 83-90.
26. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215, 89-97.
27. Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D.E.; Kustanovich, I.; Mechoulam, R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 2001, 98, 3662-3665.
28. Porter, A.C.; Sauer, J.M.; Knierman, M.D.; Becker, G.W.; Berna, M.J.; Bao, J.; Nomikos, G.G.; Carter, P.; Bymaster, F.P.; Leese, A.B. et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 2002, 301, 1020-1024.
29. Huang, S.M.; Bisogno, T.; Trevisani, M.; Al-Hayani, A.; de Petrocellis, L.; Fezza, F.; Tognetto, M.; Petros, T.J.; Krey, J.F.; Chu, C.J. et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA 2002, 99, 8400-8405.
30. Lo, V.J.; Gaetani, S.; Fu, J.; Oveisi, F.; Burton, K.; Piomelli, D. Regulation of food intake by oleoylethanolamide. Cell Mol. Life Sci. 2005, 62, 708-716.
31. Alger, B.E.; Kim, J. Supply and demand for endocannabinoids. Trends Neurosci. 2011, 34, 304-315.
32. Nomura, D.K.; Long, J.Z.; Niessen, S.; Hoover, H.S.; Ng, S.W.; Cravatt, B.F. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140, 49-61.
33. Long, J.Z.; LaCava, M.; Jin, X.; Cravatt, B.F. An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase. J. Lipid Res. 2011, 52, 337-344.
34. Stella, N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58, 1017-1030.
35. Hansen, H.S. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp. Neurol. 2010, 224, 48-55.
36. Izzo, A.A.; Sharkey, K.A. Cannabinoids and the gut: New developments and emerging concepts. Pharmacol. Ther. 2010, 126, 21-38.
37. Lauckner, J.E.; Jensen, J.B.; Chen, H.Y.; Lu, H.C.; Hille, B.; Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. USA 2008, 105, 2699-2704.
38. Overton, H.A.; Babbs, A.J.; Doel, S.M.; Fyfe, M.C.; Gardner, L.S.; Griffin, G.; Jackson, H.C.; Procter, M.J.; Rasamison, C.M.; Tang-Christensen, M. et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006, 3, 167-175.
39. Godlewski, G.; Offertaler, L.; Wagner, J.A.; Kunos, G. Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat. 2009, 89, 105-111.
40. Orio, L.; Crespo, I.; Lopez-Moreno, J.A.; Reyes-Cabello, C.; Rodriguez de Fonseca, F.; Gomez de Heras, R. Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition. Pharmacol. Biochem. Behav. 2011, 98, 220-226.
41. Cluny, N.L.; Chambers, A.P.; Vemuri, V.K.; Wood, J.T.; Eller, L.K.; Freni, C.; Reimer, R.A.; Makriyannis, A.; Sharkey, K.A. The neutral cannabinoid CB receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol. Biochem. Behav. 2011, 97, 537-543.
42. Cahill, K.; Ussher, M.H. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane. Database Syst. Rev. 2011, CD005353.
43. Gamaleddin, I.; Wertheim, C.; Zhu, A.Z.; Coen, K.M.; Vemuri, K.; Makryannis, A.; Goldberg, S.R.; Le Foll, B. Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addict. Biol. 2011, DOI: 10.1111/j.1369-1600.2011.00314.x.
44. Ishiguro, H.; Carpio, O.; Horiuchi, Y.; Shu, A.; Higuchi, S.; Schanz, N.; Benno, R.; Arinami, T.; Onaivi, E.S. A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands. Synapse 2010, 64, 92-96.
45. Agudo, J.; Martin, M.; Roca, C.; Molas, M.; Bura, A.S.; Zimmer, A.; Bosch, F.; Maldonado, R. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 2010, 53, 2629-2640.
46. Mascia, P.; Pistis, M.; Justinova, Z.; Panlilio, L.V.; Luchicchi, A.; Lecca, S.; Scherma, M.; Fratta, W.; Fadda, P.; Barnes, C. et al. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol. Psychiatry 2011, 69, 633-641.
47. Stopponi, S.; Somaini, L.; Cippitelli, A.; Cannella, N.; Braconi, S.; Kallupi, M.; Ruggeri, B.; Heilig, M.; Demopulos, G.; Gaitanaris, G. et al. Activation of nuclear PPARgamma receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol. Psychiatry 2011, 69, 642-649.
48. Gaetani, S.; Kaye, W.H.; Cuomo, V.; Piomelli, D. Role of endocannabinoids and their analogues in obesity and eating disorders. Eat. Weight Disord. 2008, 13, e42-e48.
49. Agrawal, A.; Lynskey, M.T. Candidate genes for cannabis use disorders: Findings, challenges and directions. Addiction 2009, 104, 518-532.
50. Ishiguro, H.; Onaivi, E.S.; Horiuchi, Y.; Imai, K.; Komaki, G.; Ishikawa, T.; Suzuki, M.; Watanabe, Y.; Ando, T.; Higuchi, S. et al. Functional polymorphism in the GPR55 gene is associated with anorexia nervosa. Synapse 2011, 65, 103-108.
51. Borrelli, F.; Izzo, A.A. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23, 33-49.
52. Ishac, E.J.; Jiang, L.; Lake, K.D.; Varga, K.; Abood, M.E.; Kunos, G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 1996, 118, 2023-2028.
53. Tsou, K.; Brown, S.; Sanudo-Pena, M.C.; Mackie, K.; Walker, J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83, 393-411.
54. Katona, I.; Sperlagh, B.; Sik, A.; Kafalvi, A.; Vizi, E.S.; Mackie, K.; Freund, T.F. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 1999, 19, 4544-4558.
55. Irving, A.J.; Coutts, A.A.; Harvey, J.; Rae, M.G.; Mackie, K.; Bewick, G.S.; Pertwee, R.G. Functional expression of cell surface cannabinoid CB(1) receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons. Neuroscience 2000, 98, 253-262.
56. Hohmann, A.G.; Herkenham, M. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: A double-label in situ hybridization study. Synapse 2000, 37, 71-80.
57. Gonzalez, S.; Manzanares, J.; Berrendero, F.; Wenger, T.; Corchero, J.; Bisogno, T.; Romero, J.; Fuentes, J.A.; di Marzo, V, Ramos, J.A. et al. Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland. NeuroEndocrinology 1999, 70, 137-145.
58. Coutts, A.A.; Irving, A.J.; Mackie, K.; Pertwee, R.G.; Anavi-Goffer, S. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J. Comp. Neurol. 2002, 448, 410-422.
59. Burdyga, G.; Lal, S.; Varro, A.; Dimaline, R.; Thompson, D.G.; Dockray, G.J. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J. Neurosci. 2004, 24, 2708-2715.
60. Rao, G.K.; Zhang, W.; Kaminski, N.E. Cannabinoid receptor-mediated regulation of intracellular calcium by Delta(9)-tetrahydrocannabinol in resting T cells. J. Leukoc. Biol. 2004, 75, 884-892.
61. Buchweitz, J.P.; Karmaus, P.W.; Williams, K.J.; Harkema, J.R.; Kaminski, N.E. Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol. J. Leukoc. Biol. 2008, 83, 785-796.
62. Buckley, N.E.; McCoy, K.L.; Mezey, E.; Bonner, T.; Zimmer, A.; Felder, C.C.; Glass, M.; Zimmer, A. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 2000, 396, 141-149.
63. Chuchawankul, S.; Shima, M.; Buckley, N.E.; Hartmann, C.B.; McCoy, K.L. Role of cannabinoid receptors in inhibiting macrophage costimulatory activity. Int. Immunopharmacol. 2004, 4, 265-278.
64. Van, S.; Duncan, M.; Kingsley, P.J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J.S. et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310, 329-332.
65. Gong, J.P.; Onaivi, E.S.; Ishiguro, H.; Liu, Q.R.; Tagliaferro, P.A.; Brusco, A.; Uhl, G.R. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res. 2006, 1071, 10-23.
66. Grimaldi, P.; Orlando, P.; di Siena S.; Lolicato, F.; Petrosino, S.; Bisogno, T.; Geremia, R.; de Petrocellis, L.; di Marzo, V. The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc. Natl. Acad. Sci. USA 2009, 106, 11131-11136.
67. Paria, B.C.; Das, S.K.; Dey, S.K. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc. Natl. Acad. Sci. USA 1995, 92, 9460-9464.
68. Childers, S.R.; Deadwyler, S.A. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem. Pharmacol. 1996, 52, 819-827.
69. Coffey, R.G.; Snella, E.; Johnson, K.; Pross, S. Inhibition of macrophage nitric oxide production by tetrahydrocannabinol in vivo and in vitro. Int. J. Immunopharmacol. 1996, 18, 749-752.
70. Hillard, C.J.; Manna, S.; Greenberg, M.J.; DiCamelli, R.; Ross, R.A.; Stevenson, L.A.; Murphy, V.; Pertwee, R.G.; Campbell, W.B. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 1999, 289, 1427-1433.
71. Straiker, A.J.; Borden, C.R.; Sullivan, J.M. G-protein alpha subunit isoforms couple differentially to receptors that mediate presynaptic inhibition at rat hippocampal synapses. J. Neurosci. 2002, 22, 2460-2468.
72. Shen, M.; Piser, T.M.; Seybold, V.S.; Thayer, S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 1996, 16, 4322-4334.
73. Auclair, N.; Otani, S.; Soubrie, P.; Crepel, F. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J. Neurophysiol. 2000, 83, 3287-3293.
74. Vaughan, C.W.; Connor, M.; Bagley, E.E.; Christie, M.J. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol. Pharmacol. 2000, 57, 288-295.
75. Huang, C.C.; Chen, Y.L.; Lo, S.W.; Hsu, K.S. Activation of cAMP-dependent protein kinase suppresses the presynaptic cannabinoid inhibition of glutamatergic transmission at corticostriatal synapses. Mol. Pharmacol. 2002, 61, 578-585.
76. Kawamura, Y.; Fukaya, M.; Maejima, T.; Yoshida, T.; Miura, E.; Watanabe, M.; Ohno-Shosaku, T.; Kano, M. The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J. Neurosci. 2006, 26, 2991-3001.
77. Hentges, S.T.; Low, M.J.; Williams, J.T. Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids. J. Neurosci. 2005, 25, 9746-9751.
78. Ho, J.; Cox, J.M.; Wagner, E.J. Cannabinoid-induced hyperphagia: Correlation with inhibition of proopiomelanocortin neurons? Physiol. Behav. 2007, 92, 507-519.
79. Vaughan, C.W.; McGregor, I.S.; Christie, M.J. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br. J. Pharmacol. 1999, 127, 935-940.
80. Szabo, B.; Dorner, L.; Pfreundtner, C.; Norenberg, W.; Starke, K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 1998, 85, 395-403.
81. Wallmichrath, I.; Szabo, B. Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 2002, 113, 671-682.
82. Ho, B.Y.; Stadnicka, A.; Prather, P.L.; Buckley, A.R.; Current, L.L.; Bosnjak, Z.J.; Kwok, W.M. Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells. Endocrinology 2000, 141, 1675-1685.
83. Mackie, K.; Lai, Y.; Westenbroek, R.; Mitchell, R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 1995, 15, 6552-6561.
84. Mackie, K.; Hille, B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA 1992, 89, 3825-3829.
85. Caulfield, M.P.; Brown, D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 1992, 106, 231-232.
86. Brown, S.P.; Safo, P.K.; Regehr, W.G. Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels. J. Neurosci. 2004, 24, 5623-5631.
87. Kushmerick, C.; Price, G.D.; Taschenberger, H.; Puente, N.; Renden, R.; Wadiche, J.I.; Duvoisin, R.M.; Grandes, P.; von, Gersdorff H. Retroinhibition of presynaptic Ca2+ currents by endocannabinoids released via postsynaptic mGluR activation at a calyx synapse. J. Neurosci. 2004, 24, 5955-5965.
88. Wilson, R.I.; Nicoll, R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410, 588-592.
89. Yoshida, T.; Hashimoto, K.; Zimmer, A.; Maejima, T.; Araishi, K.; Kano, M. The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells. J. Neurosci. 2002, 22, 1690-1697.
90. Diana, M.A.; Levenes, C.; Mackie, K.; Marty, A. Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. J. Neurosci. 2002, 22, 200-208.
91. Jo, Y.H.; Chen, Y.J.; Chua, S.C.; Talmage, D.A., Jr.; Role, L.W. Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 2005, 48, 1055-1066.
92. Brenowitz, S.D.; Best, A.R.; Regehr, W.G. Sustained elevation of dendritic calcium evokes widespread endocannabinoid release and suppression of synapses onto cerebellar Purkinje cells. J. Neurosci. 2006, 26, 6841-6850.
93. Ohno-Shosaku, T.; Tsubokawa, H.; Mizushima, I.; Yoneda, N.; Zimmer, A.; Kano, M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J. Neurosci. 2002, 22, 3864-3872.
94. Melis, M.; Perra, S.; Muntoni, A.L.; Pillolla, G.; Lutz, B.; Marsicano, G.; di Marzo, V., Gessa, G.L.; Pistis, M. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J. Neurosci. 2004, 24, 10707-10715.
95. Haj-Dahmane, S.; Shen, R.Y. The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. J. Neurosci. 2005, 25, 896-905.
96. van Beugen, B.J.; Nagaraja, R.Y.; Hansel, C. Climbing fiber-evoked endocannabinoid signaling heterosynaptically suppresses presynaptic cerebellar long-term potentiation. J. Neurosci. 2006, 26, 8289-8294.
97. di, S.; Malcher-Lopes, R.; Halmos, K.C.; Tasker, J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: A fast feedback mechanism. J. Neurosci. 2003, 23, 4850-4857.
98. di, S.; Malcher-Lopes, R.; Marcheselli, V.L.; Bazan, N.G.; Tasker, J.G. Rapid glucocorticoidmediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 2005, 146, 4292-4301.
99. di, S.; Maxson, M.M.; Franco, A.; Tasker, J.G. Glucocorticoids regulate glutamate and GABA synapse-specific retrograde transmission via divergent nongenomic signaling pathways. J. Neurosci. 2009, 29, 393-401.
100. Deadwyler, S.A.; Hampson, R.E.; Mu, J.; Whyte, A.; Childers, S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. 1995, 273, 734-743.
101. Mu, J.; Zhuang, S.Y.; Kirby, M.T.; Hampson, R.E.; Deadwyler, S.A. Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. J. Pharmacol. Exp. Ther. 1999, 291, 893-902.
102. Tang, S.L.; Tran, V.; Wagner, E.J. Sex differences in the cannabinoid modulation of an A-type K+ current in neurons of the mammalian hypothalamus. J. Neurophysiol. 2005, 94, 2983-2986.
103. Kellert, B.A.; Nguyen, M.C.; Nguyen, C.; Nguyen, Q.H.; Wagner, E.J. Estrogen rapidly attenuates cannabinoid-induced changes in energy homeostasis. Eur. J. Pharmacol. 2009, 622, 15-24.
104. Schweitzer, P. Cannabinoids decrease the K+ M-current in hippocampal CA1 neurons. J. Neurosci. 2000, 20, 51-58.
105. Henry, D.J.; Chavkin, C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci. Lett. 1995, 186, 91-94.
106. Lim, C.T.; Kola, B.; Korbonits, M. AMPK as a mediator of hormonal signalling. J. Mol. Endocrinol. 2010, 44, 87-97.
107. Bosier, B.; Lambert, D.M.; Hermans, E. Reciprocal influences of CB1 cannabinoid receptor agonists on ERK and JNK signalling in N1E-115 cells. FEBS Lett. 2008, 582, 3861-3867.
108. Correa, F.; Docagne, F.; Mestre, L.; Clemente, D.; Hernangomez, M.; Loria, F.; Guaza, C. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem. Pharmacol. 2009, 77, 86-100.
109. di Marzo, V.; Goparaju, S.K.; Wang, L.; Liu, J.; Batkai, S.; Jarai, Z.; Fezza, F.; Miura, G.I.; Palmiter, R.D.; Sugiura, T. et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410, 822-825.
110. Kola, B.; Farkas, I.; Christ-Crain, M.; Wittmann, G.; Lolli, F.; Amin, F.; Harvey-White, J.; Liposits, Z.; Kunos, G.; Grossman, A.B. et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One 2008, 3, e1797.
111. Malcher-Lopes, R.; di, S.; Marcheselli, V.S.; Weng, F.J.; Stuart, C.T.; Bazan, N.G.; Tasker, J.G. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J. Neurosci. 2006, 26, 6643-6650.
112. Corchero, J.; Manzanares, J.; Fuentes, J.A. Role of gonadal steroids in the corticotropin-releasing hormone and proopiomelanocortin gene expression response to Delta(9)-tetrahydrocannabinol in the hypothalamus of the rat. Neuroendocrinology 2001, 74, 185-192.
113. Diaz, S.; Farhang, B.; Hoien, J.; Stahlman, M.; Adatia, N.; Cox, J.M.; Wagner, E.J. Sex differences in the cannabinoid modulation of appetite, body temperature and neurotransmission at POMC synapses. Neuroendocrinology 2009, 89, 424-440.
114. Appleyard, S.M.; Hayward, M.; Young, J.I.; Butler, A.A.; Cone, R.D.; Rubinstein, M.; Low, M.J. A role for the endogenous opioid beta-endorphin in energy homeostasis. Endocrinology 2003, 144, 1753-1760.
115. Low, M.J.; Hayward, M.D.; Appleyard, S.M.; Rubinstein, M. State-dependent modulation of feeding behavior by proopiomelanocortin-derived beta-endorphin. Ann. N.Y. Acad. Sci. 2003, 994, 192-201.
116. Nguyen, Q.H.; Wagner, E.J. Estrogen differentially modulates the cannabinoid-induced presynaptic inhibition of amino acid neurotransmission in proopiomelanocortin neurons of the arcuate nucleus. Neuroendocrinology 2006, 84, 123-137.
117. Pagotto, U.; Marsicano, G.; Cota, D.; Lutz, B.; Pasquali, R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 2006, 27, 73-100.
118. Bermudez-Silva, F.J.; Cardinal, P.; Cota, D. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J. Psychopharmacol. 2011, in press.
119. Bensaid, M.; Gary-Bobo, M.; Esclangon, A.; Maffrand, J.P.; Le Fur, G.; Oury-Donat, F.; Soubrie, P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 2003, 63, 908-914.
120. Cota, D.; Marsicano, G.; Tschop, M.; Grubler, Y.; Flachskamm, C.; Schubert, M.; Auer, D.; Yassouridis, A.; Thone-Reineke, C.; Ortmann, S. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 2003, 112, 423-431.
121. Matias, I.; Gonthier, M.P.; Orlando, P.; Martiadis, V.; de Petrocellis, L.; Cervino, C.; Petrosino, S.; Hoareau, L.; Festy, F.; Pasquali, R. et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 2006, 91, 3171-3180.
122. Perwitz, N.; Wenzel, J.; Wagner, I.; Buning, J.; Drenckhan, M.; Zarse, K.; Ristow, M.; Lilienthal, W.; Lehnert, H.; Klein, J. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Diabetes Obes. Metab. 2010, 12, 158-166.
123. Tedesco, L.; Valerio, A.; Cervino, C.; Cardile, A.; Pagano, C.; Vettor, R.; Pasquali, R.; Carruba, M.O.; Marsicano, G.; Lutz, B. et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 2008, 57, 2028-2036.
124. Osei-Hyiaman, D.; DePetrillo, M.; Pacher, P.; Liu, J.; Radaeva, S.; Batkai, S.; Harvey-White, J.; Mackie, K.; Offertaler, L.; Wang, L. et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 2005, 115, 1298-1305.
125. Osei-Hyiaman, D.; Liu, J.; Zhou, L.; Godlewski, G.; Harvey-White, J.; Jeong, W.I.; Batkai, S.; Marsicano, G.; Lutz, B.; Buettner, C. et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J. Clin. Invest. 2008, 118, 3160-3169.
126. Edwards, C.M.; Abusnana, S.; Sunter, D.; Murphy, K.G.; Ghatei, M.A.; Bloom, S.R. The effect of the orexins on food intake: Comparison with neuropeptide Y, melanin-concentrating hormone and galanin. J. Endocrinol. 1999, 160, R7-R12.
127. Guan, J.L.; Uehara, K.; Lu, S.; Wang, Q.P.; Funahashi, H.; Sakurai, T.; Yanagizawa, M.; Shioda, S. Reciprocal synaptic relationships between orexin- and melanin-concentrating hormone-containing neurons in the rat lateral hypothalamus: A novel circuit implicated in feeding regulation. Int. J. Obes. Relat. Metab. Disord. 2002, 26, 1523-1532.
128. Minokoshi, Y.; Alquier, T.; Furukawa, N.; Kim, Y.B.; Lee, A.; Xue, B.; Mu, J.; Foufelle, F.; Ferre, P.; Birnbaum, M.J. et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004, 428, 569-574.
129. Kola, B.; Korbonits, M. Shedding light on the intricate puzzle of ghrelin's effects on appetite regulation. J. Endocrinol. 2009, 202, 191-198.
130. Costa, A.M.; Spence, K.T.; Plata-Salaman, C.R.; ffrench-Mullen, J.M. Residual Ca2+ channel current modulation by megestrol acetate via a G-protein alpha s-subunit in rat hypothalamic neurones. J. Physiol. 1995, 487, 291-303.
131. Varma, M.; Laviano, A.; Meguid, M.M.; Gleason, J.R.; Yang, Z.J.; Oler, A. Comparison of early feeding pattern dynamics in female and male rats after reversible ventromedial nucleus of hypothalamus block. J. Investig. Med. 2000, 48, 417-426.
132. Huszar, D.; Lynch, C.A.; Fairchild-Huntress, V.; Dunmore, J.H.; Fang, Q.; Berkemeier, L.R.; Gu, W.; Kesterson, R.A.; Boston, B.A.; Cone, R.D. et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88, 131-141.
133. Horvath, T.L. The hardship of obesity: A soft-wired hypothalamus. Nat. Neurosci. 2005, 8, 561-565.
134. Burdakov, D.; Ashcroft, F.M. Cholecystokinin tunes firing of an electrically distinct subset of arcuate nucleus neurons by activating A-Type potassium channels. J. Neurosci. 2002, 22, 6380-6387.
135. Cowley, M.A.; Cone, R.D.; Enriori, P.; Louiselle, I.; Williams, S.M.; Evans, A.E. Electrophysiological actions of peripheral hormones on melanocortin neurons. Ann. N.Y. Acad. Sci. 2003, 994, 175-186.
136. Plum, L.; Ma, X.; Hampel, B.; Balthasar, N.; Coppari, R.; Munzberg, H.; Shanabrough, M.; Burdakov, D.; Rother, E.; Janoschek, R. et al. Enhanced PIP3 signaling in POMC neurons causes KATP channel activation and leads to diet-sensitive obesity. J. Clin. Invest. 2006, 116, 1886-1901.
137. Claret, M.; Smith, M.A.; Batterham, R.L.; Selman, C.; Choudhury, A.I.; Fryer, L.G.; Clements, M.; Al-Qassab, H.; Heffron, H.; Xu, A.W. et al. AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. J. Clin. Invest. 2007, 117, 2325-2336.
138. Gao, Q.; Mezei, G.; Nie, Y.; Rao, Y.; Choi, C.S.; Bechmann, I.; Leranth, C.; Toran-Allerand, D.; Priest, C.A.; Roberts, J.L. et al. Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. Nat. Med. 2007, 13, 89-94.
139. Cota, D.; Proulx, K.; Smith, K.A.; Kozma, S.C.; Thomas, G.; Woods, S.C.; Seeley, R.J. Hypothalamic mTOR signaling regulates food intake. Science 2006, 312, 927-930.
140. Qiu, J.; Ronnekleiv, O.K.; Kelly, M.J. Modulation of hypothalamic neuronal activity through a novel G-protein-coupled estrogen membrane receptor. Steroids 2008, 73, 985-991.
141. Jamshidi, N.; Taylor, D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. 2001, 134, 1151-1154.
142. Gamber, K.M.; Macarthur, H.; Westfall, T.C. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 2005, 49, 646-652.
143. Sinnayah, P.; Jobst, E.E.; Rathner, J.A.; Caldera-Siu, A.D.; Tonelli-Lemos, L.; Eusterbrock, A.J.; Enriori, P.J.; Pothos, E.N.; Grove, K.L.; Cowley, M.A. Feeding induced by cannabinoids is mediated independently of the melanocortin system. PLoS One 2008, 3, e2202.
144. Tasker, J.G. Rapid glucocorticoid actions in the hypothalamus as a mechanism of homeostatic integration. Obesity (Silver Spring) 2006, 14, 259S-265S.
145. di Marzo, V.; Ligresti, A.; Cristino, L. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int. J. Obes. (Lond.) 2009, 33, S18-S24.
146. Maldonado, R.; Valverde, O.; Berrendero, F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006, 29, 225-232.
147. Kirkham, T.C.; Williams, C.M.; Fezza, F.; di Marzo, V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 2002, 136, 550-557.
148. Mahler, S.V.; Smith, K.S.; Berridge, K.C. Endocannabinoid hedonic hotspot for sensory pleasure: Anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 2007, 32, 2267-2278.
149. Kelley, A.E.; Baldo, B.A.; Pratt, W.E.; Will, M.J. Corticostriatal-hypothalamic circuitry and food motivation: Integration of energy, action and reward. Physiol. Behav. 2005, 86, 773-795.
150. Soria-Gomez, E.; Matias, I.; Rueda-Orozco, P.E.; Cisneros, M.; Petrosino, S.; Navarro, L.; di Marzo, V.; Prospero-Garcia, O. Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br. J. Pharmacol. 2007, 151, 1109-1116.
151. Himmi, T.; Dallaporta, M.; Perrin, J.; Orsini, J.C. Neuronal responses to delta 9-tetrahydrocannabinol in the solitary tract nucleus. Eur. J. Pharmacol. 1996, 312, 273-279.
152. Derbenev, A.V.; Stuart, T.C.; Smith, B.N. Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. J. Physiol. 2004, 559, 923-938.
153. Sato, I.; Arima, H.; Ozaki, N.; Watanabe, M.; Goto, M.; Hayashi, M.; Banno, R.; Nagasaki, H.; Oiso, Y. Insulin inhibits neuropeptide Y gene expression in the arcuate nucleus through GABAergic systems. J. Neurosci. 2005, 25, 8657-8664.
154. Canabal, D.D.; Song, Z.; Potian, J.G.; Beuve, A.; McArdle, J.J.; Routh, V.H. Glucose, insulin, and leptin signaling pathways modulate nitric oxide synthesis in glucose-inhibited neurons in the ventromedial hypothalamus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292, R1418-R1428.
155. Kubota, N.; Yano, W.; Kubota, T.; Yamauchi, T.; Itoh, S.; Kumagai, H.; Kozono, H.; Takamoto, I.; Okamoto, S.; Shiuchi, T. et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 2007, 6, 55-68.
156. Guillod-Maximin, E.; Roy, A.F.; Vacher, C.M.; Aubourg, A.; Bailleux, V.; Lorsignol, A.; Penicaud, L.; Parquet, M.; Taouis, M. Adiponectin receptors are expressed in hypothalamus and colocalized with proopiomelanocortin and neuropeptide Y in rodent arcuate neurons. J. Endocrinol. 2009, 200, 93-105.
157. Park, S.; Kim, D.S.; Kwon, D.Y.; Yang, H.J. Long-term central infusion of adiponectin improves energy and glucose homeostasis by decreasing fat storage and suppressing hepatic gluconeogenesis without changing food intake. J. Neuroendocrinol. 2011, DOI: 10.1111/j.1365-2826.2011.02165.x.
158. Appleyard, S.M.; Bailey, T.W.; Doyle, M.W.; Jin, Y.H.; Smart, J.L.; Low, M.J.; Andresen, M.C. Proopiomelanocortin neurons in nucleus tractus solitarius are activated by visceral afferents: Regulation by cholecystokinin and opioids. J. Neurosci. 2005, 25, 3578-3585.
159. Tsujino, N.; Yamanaka, A.; Ichiki, K.; Muraki, Y.; Kilduff, T.S.; Yagami, K.; Takahashi, S.; Goto, K.; Sakurai, T. Cholecystokinin activates orexin/hypocretin neurons through the cholecystokinin A receptor. J. Neurosci. 2005, 25, 7459-7469.
160. Sutton, G.M.; Duos, B.; Patterson, L.M.; Berthoud, H.R. Melanocortinergic modulation of cholecystokinin-induced suppression of feeding through extracellular signal-regulated kinase signaling in rat solitary nucleus. Endocrinology 2005, 146, 3739-3747.
161. Babic, T.; Townsend, R.L.; Patterson, L.M.; Sutton, G.M.; Zheng, H.; Berthoud, H.R. Phenotype of neurons in the nucleus of the solitary tract that express CCK-induced activation of the ERK signaling pathway. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296, R845-R854.
162. Kang, K.S.; Yahashi, S.; Azuma, M.; Matsuda, K. The anorexigenic effect of cholecystokinin octapeptide in a goldfish model is mediated by the vagal afferent and subsequently through the melanocortin- and corticotropin-releasing hormone-signaling pathways. Peptides 2010, 31, 2130-2134.
163. Batterham, R.L.; Bloom, S.R. The gut hormone peptide YY regulates appetite. Ann. N.Y. Acad. Sci. 2003, 994, 162-168.
164. Challis, B.G.; Pinnock, S.B.; Coll, A.P.; Carter, R.N.; Dickson, S.L.; O'Rahilly, S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem. Biophys. Res. Commun. 2003, 311, 915-919.
165. Halatchev, I.G.; Ellacott, K.L.; Fan, W.; Cone, R.D. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 2004, 145, 2585-2590.
166. Ghamari-Langroudi, M.; Colmers, W.F.; Cone, R.D. PYY3-36 inhibits the action potential firing activity of POMC neurons of arcuate nucleus through postsynaptic Y2 receptors. Cell Metab. 2005, 2, 191-199.
167. Acuna-Goycolea, C.; van den Pol, A.N. Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: Implications for hypothalamic regulation of energy homeostasis. J. Neurosci. 2005, 25, 10510-10519.
168. Parkinson, J.R.; Dhillo, W.S.; Small, C.J.; Chaudhri, O.B.; Bewick, G.A.; Pritchard, I.; Moore, S.; Ghatei, M.A.; Bloom, S.R. PYY3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones. Am. J. Physiol. Endocrinol. Metab. 2008, 294, E698-E708.
169. Andersson, U.; Filipsson, K.; Abbott, C.R.; Woods, A.; Smith, K.; Bloom, S.R.; Carling, D.; Small, C.J. AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 2004, 279, 12005-12008.
170. Stricker-Krongrad, A.; Beck, B. Modulation of hypothalamic hypocretin/orexin mRNA expression by glucocorticoids. Biochem. Biophys. Res. Commun. 2002, 296, 129-133.
171. Christ-Crain, M.; Kola, B.; Lolli, F.; Fekete, C.; Seboek, D.; Wittmann, G.; Feltrin, D.; Igreja, S.C.; Ajodha, S.; Harvey-White, J. et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: A novel mechanism in Cushing's syndrome. FASEB J. 2008, 22, 1672-1683.
172. Unger, E.K.; Piper, M.L.; Olofsson, L.E.; Xu, A.W. Functional role of c-Jun-N-terminal kinase in feeding regulation. Endocrinology 2010, 151, 671-682.
173. Malyala, A.; Zhang, C.; Bryant, D.N.; Kelly, M.J.; Ronnekleiv, O.K. PI3K signaling effects in hypothalamic neurons mediated by estrogen. J. Comp. Neurol. 2008, 506, 895-911.
174. Dewing, P.; Christensen, A.; Bondar, G.; Micevych, P. Protein kinase C signaling in the hypothalamic arcuate nucleus regulates sexual receptivity in female rats. Endocrinology 2008, 149, 5934-5942.
175. Jeffery, G.S.; Peng, K.C.; Wagner, E.J. The role of phosphatidylinositol-3-kinase and AMP-activated kinase in the rapid estrogenic attentuation of cannabinoid-induced changes in energy homeostasis. Pharmaceuticals 2011, 4, 630-651.
176. Ibrahim, N.; Bosch, M.A.; Smart, J.L.; Qiu, J.; Rubinstein, M.; Ronnekleiv, O.K.; Low, M.J.; Kelly, M.J. Hypothalamic proopiomelanocortin neurons are glucose responsive and express K(ATP) channels. Endocrinology 2003, 144, 1331-1340.
177. Burdakov, D.; Luckman, S.M.; Verkhratsky, A. Glucose-sensing neurons of the hypothalamus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2005, 360, 2227-2235.
178. Burdakov, D.; Jensen, L.T.; Alexopoulos, H.; Williams, R.H.; Fearon, I.M.; O'Kelly, I.; Gerasimenko, O.; Fugger, L.; Verkhratsky, A. Tandem-pore K+ channels mediate inhibition of orexin neurons by glucose. Neuron 2006, 50, 711-722.
179. Parton, L.E.; Ye, C.P.; Coppari, R.; Enriori, P.J.; Choi, B.; Zhang, C.Y.; Xu, C.; Vianna, C.R.; Balthasar, N.; Lee, C.E. et al. Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity. Nature 2007, 449, 228-232.
180. Yang, X.J.; Mastaitis, J.; Mizuno, T.; Mobbs, C.V. Glucokinase regulates reproductive function, glucocorticoid secretion, food intake, and hypothalamic gene expression. Endocrinology 2007, 148, 1928-1932.
181. Morgan, K.; Obici, S.; Rossetti, L. Hypothalamic responses to long-chain fatty acids are nutritionally regulated. J. Biol. Chem. 2004, 279, 31139-31148.
182. Fan, C.; Liu, X.; Shen, W.; Deckelbaum, R.J.; Qi, K. The regulation of leptin, leptin receptor and pro-opiomelanocortin expression by N-3 PUFAs in diet-induced obese mice is not related to the methylation of their promoters. Nutr. Metab. (Lond.) 2011, 8, 31.
183. Gardner, E.L. Endocannabinoid signaling system and brain reward: Emphasis on dopamine. Pharmacol. Biochem. Behav. 2005, 81, 263-284.
184. Hyman, S.E.; Malenka, R.C.; Nestler, E.J. Neural mechanisms of addiction: The role of reward-related learning and memory. Annu. Rev. Neurosci. 2006, 29, 565-598.
185. Koob, G.F.; Moal, M.L. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat. Neurosci. 2005, 8, 1442-1444.
186. Nestler, E.J. Is there a common molecular pathway for addiction? Nat. Neurosci. 2005, 8, 1445-1449.
187. Solinas, M.; Goldberg, S.R.; Piomelli, D. The endocannabinoid system in brain reward processes. Br. J. Pharmacol. 2008, 154, 369-383.
188. Melis, M.; Pistis, M.; Perra, S.; Muntoni, A.L.; Pillolla, G.; Gessa, G.L. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci. 2004, 24, 53-62.
189. Wiskerke, J.; Pattij, T.; Schoffelmeer, A.N.; de Vries, T.J. The role of CB1 receptors in psychostimulant addiction. Addict. Biol. 2008, 13, 225-238.
190. Vinod, K.Y.; Kassir, S.A.; Hungund, B.L.; Cooper, T.B.; Mann, J.J.; Arango, V. Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. J. Psychiatr. Res. 2010, 44, 591-597.
191. Adamczyk, P.; McCreary, A.C.; Przegalinski, E.; Mierzejewski, P.; Bienkowski, P.; Filip, M. The effects of fatty acid amide hydrolase inhibitors on maintenance of cocaine and food self-administration and on reinstatement of cocaine-seeking and food-taking behavior in rats. J. Physiol. Pharmacol. 2009, 60, 119-125.
192. Forget, B.; Coen, K.M.; Le Foll, B. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration-comparison with CB(1) receptor blockade. Psychopharmacology (Berl.) 2009, 205, 613-624.
193. Dlugos, A.M.; Hamidovic, A.; Hodgkinson, C.A.; Goldman, D.; Palmer, A.A.; de Wit, H. More aroused, less fatigued: Fatty acid amide hydrolase gene polymorphisms influence acute response to amphetamine. Neuropsychopharmacology 2010, 35, 613-622.
194. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th ed.; American Psychiatric Association: Washington, DC, USA, 1994.
195. Walker, A. Thesaurus of Psychological Index Terms, 7th ed.; American Psychiatric Association: Washintong, DC, USA, 1994.
196. Volkow, N.D.; Wise, R.A. How can drug addiction help us understand obesity? Nat. Neurosci. 2005, 8, 555-560.
197. Kaye, W. Neurobiology of anorexia and bulimia nervosa. Physiol. Behav. 2008, 94, 121-135.
198. Lowe, B.; Zipfel, S.; Buchholz, C.; Dupont, Y.; Reas, D.L.; Herzog, W. Long-term outcome of anorexia nervosa in a prospective 21-year follow-up study. Psychol. Med. 2001, 31, 881-890.
199. Strober, M.; Schmidt-Lackner, S.; Freeman, R.; Bower, S.; Lampert, C.; DeAntonio, M. Recovery and relapse in adolescents with bipolar affective illness: A five-year naturalistic, prospective follow-up. J. Am. Acad. Child Adolesc. Psychiatry 1995, 34, 724-731.
200. Bulik, C.M.; Sullivan, P.F.; Kendler, K.S. Heritability of binge-eating and broadly defined bulimia nervosa. Biol. Psychiatry 1998, 44, 1210-1218.
201. Klump, K.L.; Miller, K.B.; Keel, P.K.; McGue, M.; Iacono, W.G. Genetic and environmental influences on anorexia nervosa syndromes in a population-based twin sample. Psychol. Med. 2001, 31, 737-740.
202. Kaye, W.H.; Nagata, T.; Weltzin, T.E.; Hsu, L.K.; Sokol, M.S.; McConaha, C.; Plotnicov, K.H.; Weise, J.; Deep, D. Double-blind placebo-controlled administration of fluoxetine in restrictingand restricting-purging-type anorexia nervosa. Biol. Psychiatry 2001, 49, 644-652.
203. Walsh, B.T.; Kaplan, A.S.; Attia, E.; Olmsted, M.; Parides, M.; Carter, J.C.; Pike, K.M.; Devlin, M.J.; Woodside, B.; Roberto, C.A.; Rockert, W. Fluoxetine after weight restoration in anorexia nervosa: A randomized controlled trial. JAMA, J. Am. Med. Assoc. 2006, 295, 2605-2612.
204. Stoving, R.K.; Ries, A.; Brixen, K.; Flyvbjerg, A.; Horder, K.; Frystyk, J. Leptin, ghrelin, and endocannabinoids: Potential therapeutic targets in anorexia nervosa. J. Psychiatr. Res. 2009, 43, 671-679.
205. Monteleone, P.; Castaldo, E.; Maj, M. Neuroendocrine dysregulation of food intake in eating disorders. Regul. Pept. 2008, 149, 39-50.
206. Monteleone, P.; DiLieto, A.; Castaldo, E.; Maj, M. Leptin functioning in eating disorders. CNS Spectr. 2004, 9, 523-529.
207. Holtkamp, K.; Herpertz-Dahlmann, B.; Hebebrand, K.; Mika, C.; Kratzsch, J.; Hebebrand, J. Physical activity and restlessness correlate with leptin levels in patients with adolescent anorexia nervosa. Biol. Psychiatry 2006, 60, 311-313.
208. Monteleone, P.; Matias, I.; Martiadis, V.; de Petrocellis, L.; Maj, M.; di Marzo, V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005, 30, 1216-1221.
209. Frieling, H.; Albrecht, H.; Jedtberg, S.; Gozner, A.; Lenz, B.; Wilhelm, J.; Hillemacher, T.; de Zwaan, M.; Kornhuber, J.; Bleich, S. Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders. Psychoneuroendocrinology 2009, 34, 620-624.
210. Fu, J.; Gaetani, S.; Oveisi, F.; Lo Verme, J.; Serrano, A.; Rodriguez de Fonseca, F.; Rosengarth, A.; Luecke, H.; di Giacomo, B.; Tarzia, G. et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003, 425, 90-93.
211. Siegfried, Z.; Kanyas, K.; Latzer, Y.; Karni, O.; Bloch, M.; Lerer, B.; Berry, E.M. Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: Differences between restricting and binging/purging subtypes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 125B, 126-130.
212. Muller, T.D.; Reichwald, K.; Bronner, G.; Kirschner, J.; Nguyen, T.T.; Scherag, A.; Herzog, W.; Herpertz-Dahlmann, B.; Lichtner, P.; Meitinger, T. et al. Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa. Child Adolesc. Psychiatry Ment. Health 2008, 2, 33.
213. Monteleone, P.; Tortorella, A.; Martiadis, V.; di Filippo, C.; Canestrelli, B.; Maj, M. The cDNA 385C to A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) is associated with overweight/obesity but not with binge eating disorder in overweight/obese women. Psychoneuroendocrinology 2008, 33, 546-550.
214. Monteleone, P.; Bifulco, M.; di Filippo C.; Gazzerro, P.; Canestrelli, B.; Monteleone, F.; Proto, M.C.; di Genio, M.; Grimaldi, C.; Maj, M. Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: Evidence for synergistic effects. Genes Brain Behav. 2009, 8, 728-732.
215. Nelson, K.; Walsh, D.; Deeter, P.; Sheehan, F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J. Palliat. Care 1994, 10, 14-18.
216. Beal, J.E.; Olson, R.; Laubenstein, L.; Morales, J.O.; Bellman, P.; Yangco, B.; Lefkowitz, L.; Plasse, T.F.; Shepard, K.V. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manage. 1995, 10, 89-97.
217. Lewis, D.Y.; Brett, R.R. Activity-based anorexia in C57/BL6 mice: Effects of the phytocannabinoid, Delta9-tetrahydrocannabinol (THC) and the anandamide analogue, OMDM-2. Eur. Neuropsychopharmacol. 2010, 20, 622-631.
218. Verty, A.N.; Evetts, M.J.; Crouch, G.J.; McGregor, I.S.; Stefanidis, A.; Oldfield, B.J. The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia. Neuropsychopharmacology 2011, 36, 1349-1358.
219. Gross, H.; Ebert, M.H.; Faden, V.B.; Goldberg, S.C.; Kaye, W.H.; Caine, E.D.; Hawks, R.; Zinberg, N. A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. J. Clin. Psychopharmacol. 1983, 3, 165-171.
220. Naruse, T.; Amano, H.; Koizumi, Y. Possible involvement of dopamine D-1 and D-2 receptors in diazepam-induced hyperphagia in rats. Fundam. Clin. Pharmacol. 1991, 5, 677-693.
221. Weisser, S.B.; McLarren, K.W.; Voglmaier, N.; van Netten-Thomas, C.J.; Antov, A.; Flavell, R.A.; Sly, L.M. Alternative activation of macrophages by IL-4 requires SHIP degradation. Eur. J. Immunol. 2011, 41, 1742-1753.
222. Kaczocha, M.; Glaser, S.T.; Chae, J.; Brown, D.A.; Deutsch, D.G. Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2. J. Biol. Chem. 2010, 285, 2796-2806.
223. Melis, M.; Pillolla, G.; Luchicchi, A.; Muntoni, A.L.; Yasar, S.; Goldberg, S.R.; Pistis, M. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J. Neurosci. 2008, 28, 13985-13994.
224. Sipe, J.C.; Chiang, K.; Gerber, A.L.; Beutler, E.; Cravatt, B.F. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl. Acad. Sci. USA 2002, 99, 8394-8399.
225. Wei, B.Q.; Mikkelsen, T.S.; McKinney, M.K.; Lander, E.S.; Cravatt, B.F. A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem. 2006, 281, 36569-36578.
226. Valina, A.L.; Mazumder-Shivakumar, D.; Bruice, T.C. Probing the Ser-Ser-Lys catalytic triad mechanism of peptide amidase: Computational studies of the ground state, transition state, and intermediate. Biochemistry 2004, 43, 15657-15672.
227. Giang, D.K.; Cravatt, B.F. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl. Acad. Sci. USA 1997, 94, 2238-2242.
228. Díez-Roux, G.; Banfi, S.; Sultan, M.; Geffers, L.; Anand, S.; Rozado, D.; Magen, A.; Canidio, E.; Pagani, M.; Peluso, I. et al. A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS Biol. 2011, 9, e1000582.
229. Nestler, E.J.; Landsman, D. Learning about addiction from the genome. Nature 2001, 409, 834-835.
230. Xu, M.; Zhang, J. Molecular genetic probing of dopamine receptors in drug addiction. Curr. Opin. Drug Discov. Devel. 2004, 7, 703-708.
231. Russo, P.; Cesario, A.; Rutella, S.; Veronesi, G.; Spaggiari, L.; Galetta, D.; Margaritora, S.; Granone, P.; Greenberg, D.S. Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment. Curr. Med. Chem. 2011, 18, 91-112.
232. Panula, P.; Nuutinen, S. Histamine and H3 receptor in alcohol-related behaviors. J. Pharmacol. Exp. Ther. 2011, 336, 9-16.
233. Sipe, J.C.; Waalen, J.; Gerber, A.; Beutler, E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int. J. Obes. (Lond.) 2005, 29, 755-759.
234. Flanagan, J.M.; Gerber, A.L.; Cadet, J.L.; Beutler, E.; Sipe, J.C. The fatty acid amide hydrolase 385 A/A (P129T) variant: Haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum. Genet. 2006, 120, 581-588.
235. Tyndale, R.F.; Payne, J.I.; Gerber, A.L.; Sipe, J.C. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: Studies of drug use and dependence in Caucasians. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B, 660-666.
236. Doehring, A.; Geisslinger, G.; Lotsch, J. Rapid screening for potentially relevant polymorphisms in the human fatty acid amide hydrolase gene using Pyrosequencing. Prostaglandins Other Lipid Mediat. 2007, 84, 128-137.
237. Moreira, F.A.; Kaiser, N.; Monory, K.; Lutz, B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008, 54, 141-150.
238. Cravatt, B.F.; Demarest, K.; Patricelli, M.P.; Bracey, M.H.; Giang, D.K.; Martin, B.R.; Lichtman, A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 2001, 98, 9371-9376.
239. Blednov, Y.A.; Cravatt, B.F.; Boehm, S.L.; Walker, D.; Harris, R.A. Role of endocannabinoids in alcohol consumption and intoxication: Studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology 2007, 32, 1570-1582.
240. Schacht, J.P.; Selling, R.E.; Hutchison, K.E. Intermediate cannabis dependence phenotypes and the FAAH C385A variant: An exploratory analysis. Psychopharmacology (Berl) 2009, 203, 511-517.
241. Endsley, M.P.; Thill, R.; Choudhry, I.; Williams, C.L.; Kajdacsy-Balla, A.; Campbell, W.B.; Nithipatikom, K. Expression and function of fatty acid amide hydrolase in prostate cancer. Int. J. Cancer 2008, 123, 1318-1326.
242. Pietrzykowski, A.Z. The role of microRNAs in drug addiction: A big lesson from tiny molecules. Int. Rev. Neurobiol. 2010, 91, 1-24.
243. Merritt, L.L.; Martin, B.R.; Walters, C.; Lichtman, A.H.; Damaj, M.I. The endogenous cannabinoid system modulates nicotine reward and dependence. J. Pharmacol. Exp. Ther. 2008, 326, 483-492.
244. Ahn, K.; Johnson, D.S.; Cravatt, B.F. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert. Opin. Drug Discov. 2009, 4, 763-784.
245. Waleh, N.S.; Cravatt, B.F.; Apte-Deshpande, A.; Terao, A.; Kilduff, T.S. Transcriptional regulation of the mouse fatty acid amide hydrolase gene. Gene 2002, 291, 203-210.
246. Gasperi, V.; Fezza, F.; Spagnuolo, P.; Pasquariello, N.; Maccarrone, M. Further insights into the regulation of human FAAH by progesterone and leptin implications for endogenous levels of anandamide and apoptosis of immune and neuronal cells. Neurotoxicology 2005, 26, 811-817.
247. Grimaldi, P.; Rossi, G.; Catanzaro, G.; Maccarrone, M. Modulation of the endocannabinoiddegrading enzyme fatty acid amide hydrolase by follicle-stimulating hormone. Vitam. Horm. 2009, 81, 231-261.